Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Kymera Therapeutics starts Phase 2 trial of KT-474 (SAR444656), a new IRAK4 degrader, on its first Hidradenitis Suppurativa patient
3 November 2023
Kymera Therapeutics discloses initiation of Phase 2 trial with KT-474 (SAR444656), a novel IRAK4 degrader, being administered to its first Hidradenitis Suppurativa patient.
Bio Sequence
3 min read
The Evolution of the Competitive Landscape Behind Regeneron's Pleasing Sales of High-dose Treatment for Macular Degeneration, Eylea
3 November 2023
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Aflibercept patent are Novartis with 80 applications, Regeneron with 60 applications, and Sanofi with 50 applications.
Latest Hotspot
3 min read
Otsuka Pharmaceutical unveils Phase 3 studies of Centanafadine for treating Attention Deficit Hyperactivity Disorder in children and teenagers
2 November 2023
Otsuka Pharmaceutical, including its U.S. division, reported promising results from two Phase 3 trials evaluating centanafadine's efficacy and safety in managing ADHD in children and teens.
Drug Insights
5 min read
An In-depth Analysis of Ezetimibe/Simvastatin's R&D Progress and Mechanism of Action on Drug Target
2 November 2023
This article summarized the latest R&D progress of Ezetimibe/Simvastatin, the mechanism of action for Ezetimibe/Simvastatin, and the drug target R&D trends for Ezetimibe/Simvastatin.
Latest Hotspot
3 min read
ImmunoGen Announces EMA Approval of Mirvetuximab Soravtansine's Application for Treating Platinum-Resistant Ovarian Cancer
2 November 2023
ImmunoGen Discloses European Medicines Agency Approval of Mirvetuximab Soravtansine's Marketing Authorization Application for Dealing with Platinum-Resistant Ovarian Cancer.
Drug Insights
4 min read
Fam-trastuzumab deruxtecan-NXKI: Detailed Review of its Transformative R&D Success
2 November 2023
This article summarized the latest R&D progress of Fam-trastuzumab deruxtecan-NXKI, the mechanism of action for Fam-trastuzumab deruxtecan-NXKI, and the drug target R&D trends for Fam-trastuzumab deruxtecan-NXKI.
Latest Hotspot
3 min read
TransCode Therapeutics unveils extended lifespan in mouse models of Glioblastoma treated by its prime candidate, TTX-MC138
2 November 2023
TransCode Therapeutics, Inc., an RNA oncology specialist, today announced improved survival rates in mouse models with human glioblastoma multiforme tumors after treatment with their leading candidate, TTX-MC138.
Drug Insights
4 min read
Unleashing the Power of Doxycycline Calcium: A Comprehensive Review on R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Doxycycline Calcium, the Mechanism of Action for Doxycycline Calcium, and the drug target R&D trends for Doxycycline Calcium.
Latest Hotspot
3 min read
The U.S. FDA grants Santhera approval for AGAMREE® (vamorolone) as a therapeutic for Duchenne Muscular Dystrophy
2 November 2023
Santhera Pharmaceuticals has confirmed that the FDA has granted approval for AGAMREE® (vamorolone) oral suspension 40 mg/ml.
Drug Insights
4 min read
Ciltacabtagene autoleucel Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Ciltacabtagene autoleucel, the Mechanism of Action for Ciltacabtagene autoleucel, and the drug target R&D trends for Ciltacabtagene autoleucel.
Latest Hotspot
3 min read
The commencement of Phase III SAR-bisPSMA by Clarity and PSI has been initiated
2 November 2023
Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.
Drug Insights
3 min read
Unleashing the Power of Clocortolone Pivalate: A Comprehensive Review on R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Clocortolone Pivalate, the Mechanism of Action for Clocortolone Pivalate, and the drug target R&D trends for Clocortolone Pivalate.